Login to Your Account



SeaGen, Genentech Conjugate Verb 'to Deal' with Wider Pact

By Jennifer Boggs


Wednesday, August 4, 2010
Genentech Inc. is turning again to Seattle Genetics Inc.'s antibody-drug conjugate platform, as the Bothell, Wash.-based biotech racks up additional licensing fees ahead of anticipated Phase III data and marketing submissions for lead internal lymphoma drug SGN-35. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription